Effects of Cortical Dopamine Regulation on Drinking, Craving, and Cognitive Control

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-01

Study Completion Date

2021-04-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether the catechol-O-methyltransferase (COMT) inhibitor tolcapone, relative to placebo, reduces alcohol drinking and alcohol cue-elicited brain activation and increases brain activation associated with cognitive control as a function of a participant's genotype at a polymorphism in the COMT gene.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

COMT Inhibition Among Individuals With Comorbid AUD/ADHD

NCT03904498

Alcohol Use Disorder Attention Deficit Hyperactivity Disorder

RECRUITING PHASE2

A Study of Neural Circuit Responses to Catechol-O-methyl Transferase (COMT) Inhibitors

NCT01158950

Impulsive Behavior

COMPLETED NA

Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users

NCT02740582

Alcohol Abuse Impulsive Behavior

COMPLETED PHASE2

Family History Study of Alcohol Consumption Using Memantine

NCT00630955

Alcohol Drinking

COMPLETED PHASE2

Aripiprazole Effects on Alcohol Drinking and Craving

NCT01292057

Alcohol Dependence

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo/rs4680 val/val

Placebo three times per day for eight days

Individuals with the rs4680 val/val genotype

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Tolcapone/rs4680 val/val

Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days

Individuals with the rs4680 val/val genotype

Group Type ACTIVE_COMPARATOR

Tolcapone

Intervention Type DRUG

Placebo/rs4680 val/met

Placebo three times per day for eight days

Individuals with the rs4680 val/met genotype

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Tolcapone/rs4680 val/met

Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days

Individuals with the rs4680 val/met genotype

Group Type ACTIVE_COMPARATOR

Tolcapone

Intervention Type DRUG

Placebo/rs4680 met/met

Placebo three times per day for eight days

Individuals with the rs4680 met/met genotype

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Tolcapone/rs4680 met/met

Tolcapone 100 mg three times per day for three days Tolcapone 200 mg three times per day for five days

Individuals with the rs4680 met/met genotype

Group Type ACTIVE_COMPARATOR

Tolcapone

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tolcapone

Intervention Type DRUG

Placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tasmar

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 21-40 (to focus on an age group still on a trajectory of increasing alcohol consumption).
2. Meets Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria for current Alcohol Use Disorder.
3. Currently not engaged in, and does not want treatment for, alcohol-related problems.
4. Able to read and understand questionnaires and informed consent.
5. Lives within 50 miles of the study site.
6. Able to maintain abstinence from alcohol for two days (without the aid of detoxification medications), as determined by self report and breathalyzer measurements.

Exclusion Criteria

1. Current DSM-5 diagnosis of any other substance use disorder except Nicotine Use Disorder.
2. Any psychoactive substance use (except marijuana and nicotine) within the last 30 days, as indicated by self-report and urine drug screen. For marijuana, no use within the last seven days by verbal report and negative (or decreasing) urine tetrahydrocannibinol (THC) levels.
3. Current DSM-5 Axis I diagnosis, including major depression, panic disorder, obsessive-compulsive disorder, post-traumatic stress disorder, bipolar affective disorder, schizophrenia, dissociative disorders, eating disorders, or any other psychotic or organic mental disorder.
4. Current suicidal ideation or homicidal ideation.
5. Need for maintenance or acute treatment with any psychoactive medication, including antiepileptic medications.
6. Currently taking medication known to affect alcohol intake (e.g., disulfiram, naltrexone, acamprosate, topiramate).
7. History of severe alcohol withdrawal (e.g., seizure, delirium tremens), as evidenced by self-report and assessment with Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar).
8. Clinically significant medical problems such as cardiovascular, renal, gastrointestinal, or endocrine problems that would impair participation or limit medication ingestion.
9. Past alcohol-related medical illness, such as gastrointestinal bleeding, pancreatitis, or peptic ulcer.
10. Current or past hepatocellular disease, as indicated by verbal report or elevations of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than the upper limit of the normal range at screening.
11. Females of childbearing potential who are pregnant (by urine human chorionic gonadotropin), nursing, or who are not using a reliable form of birth control.
12. Current charges pending for a violent crime (not including drinking while intoxicated).
13. Lack of a stable living situation.
14. Presence of ferrous metal in the body, as evidenced by metal screening and self-report.
15. Severe claustrophobia or morbid obesity that preclude placement in the MRI scanner.
16. History of head injury with \> 2 minutes of unconsciousness.

Minimum Eligible Age

21 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No